BIOMAT Database Logo BIOMAT Database Logo

Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine). The MST-16 Study Group. 1993

R Ohno, and T Masaoka, and S Shirakawa, and S Sakamoto, and M Hirano, and S Hanada, and K Yasunaga, and S Yokomaku, and Y Mitomo, and K Nagai
Department of Medicine, Nagoya University School of Medicine, Japan.

BACKGROUND MST-16, a new orally administered bis(2,6-dioxopiperazine) analogue and an inhibitor of topoisomerase II, was given to 24 patients with adult T-cell leukemia-lymphoma (ATLL) in a Phase I-II multi-institutional cooperative study. METHODS MST-16 was administered orally daily for 7 days, with courses repeated at intervals of 2-3 weeks in 24 patients. RESULTS Two complete remissions (CR) and eight partial remissions (PR) were obtained in 23 evaluable patients who received 1200-2800 mg/day of MST-16. Among 13 acute-type ATLL, one CR and five PR were obtained. Among eight lymphoma-type ATLL, two PR were detected. Among two chronic-type ATLL, one CR and one PR occurred. Remissions were obtained at 7-232 days (median, 23 days) and lasted 43-374 days (median, 68 days). The major toxic effects were leukopenia (68%), anemia (52%), thrombocytopenia (35%), and gastrointestinal disorders (22%). CONCLUSIONS MST-16 was shown to be effective in ATLL, which has no standard therapy. This drug deserves further clinical trials because it shows little cross resistance to currently available antitumor drugs.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D002415 Cats The domestic cat, Felis catus, of the carnivore family FELIDAE, comprising over 30 different breeds. The domestic cat is descended primarily from the wild cat of Africa and extreme southwestern Asia. Though probably present in towns in Palestine as long ago as 7000 years, actual domestication occurred in Egypt about 4000 years ago. (From Walker's Mammals of the World, 6th ed, p801) Felis catus,Felis domesticus,Domestic Cats,Felis domestica,Felis sylvestris catus,Cat,Cat, Domestic,Cats, Domestic,Domestic Cat
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

R Ohno, and T Masaoka, and S Shirakawa, and S Sakamoto, and M Hirano, and S Hanada, and K Yasunaga, and S Yokomaku, and Y Mitomo, and K Nagai
MST-16, a novel derivative of bis(2,6-dioxopiperazine), synergistically enhances the antitumor effects of anthracyclines.
January 1998, Cancer chemotherapy and pharmacology,
R Ohno, and T Masaoka, and S Shirakawa, and S Sakamoto, and M Hirano, and S Hanada, and K Yasunaga, and S Yokomaku, and Y Mitomo, and K Nagai
Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models.
January 1990, Cancer chemotherapy and pharmacology,
R Ohno, and T Masaoka, and S Shirakawa, and S Sakamoto, and M Hirano, and S Hanada, and K Yasunaga, and S Yokomaku, and Y Mitomo, and K Nagai
Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine).
January 1991, Cancer chemotherapy and pharmacology,
R Ohno, and T Masaoka, and S Shirakawa, and S Sakamoto, and M Hirano, and S Hanada, and K Yasunaga, and S Yokomaku, and Y Mitomo, and K Nagai
Effective treatment of adult T cell leukemia/lymphoma with a novel oral antitumor agent, MST-16.
January 1992, Oncology,
R Ohno, and T Masaoka, and S Shirakawa, and S Sakamoto, and M Hirano, and S Hanada, and K Yasunaga, and S Yokomaku, and Y Mitomo, and K Nagai
Phase II study: treatment of non-Hodgkin's lymphoma with an oral antitumor derivative of bis(2,6-dioxopiperazine).
March 1992, Journal of the National Cancer Institute,
R Ohno, and T Masaoka, and S Shirakawa, and S Sakamoto, and M Hirano, and S Hanada, and K Yasunaga, and S Yokomaku, and Y Mitomo, and K Nagai
MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy.
December 1999, Clinical cancer research : an official journal of the American Association for Cancer Research,
R Ohno, and T Masaoka, and S Shirakawa, and S Sakamoto, and M Hirano, and S Hanada, and K Yasunaga, and S Yokomaku, and Y Mitomo, and K Nagai
Dioxopiperazine derivative potentiates antitumor effect of methylglyoxal bis(cyclopentylamidinohydrazone) on human and mouse leukemia cells.
January 1994, Anticancer research,
R Ohno, and T Masaoka, and S Shirakawa, and S Sakamoto, and M Hirano, and S Hanada, and K Yasunaga, and S Yokomaku, and Y Mitomo, and K Nagai
Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
September 1991, Cancer research,
R Ohno, and T Masaoka, and S Shirakawa, and S Sakamoto, and M Hirano, and S Hanada, and K Yasunaga, and S Yokomaku, and Y Mitomo, and K Nagai
[Treatment of adult T-cell leukemia-lymphoma].
June 1994, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
R Ohno, and T Masaoka, and S Shirakawa, and S Sakamoto, and M Hirano, and S Hanada, and K Yasunaga, and S Yokomaku, and Y Mitomo, and K Nagai
[Treatment of adult T-cell leukemia-lymphoma].
October 2014, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Copied contents to your clipboard!